German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Kim Magaly Pabst in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
Search for other papers by Robert Seifert in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Nader Hirmas in
Google Scholar
PubMed
Search for other papers by Martina Broecker-Preuss in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Manuel Weber in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Wolfgang Peter Fendler in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Timo Bartel in
Google Scholar
PubMed
Institute of Pathology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
Search for other papers by Sarah Theurer in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Ken Herrmann in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Rainer Görges in
Google Scholar
PubMed
a maximum of 64 months ( 6 ). Primary endpoint of this study was to determine the predictive power for recurrence-free survival (RFS) of the different cut-off values of s-Tg (≤24 months after completion of primary therapy) and u-hsTg (6 ± 3 months
Search for other papers by June Young Choi in
Google Scholar
PubMed
Search for other papers by Jin Wook Yi in
Google Scholar
PubMed
Search for other papers by Jun Hyup Lee in
Google Scholar
PubMed
Search for other papers by Ra-Yeong Song in
Google Scholar
PubMed
Search for other papers by Hyeongwon Yu in
Google Scholar
PubMed
Search for other papers by Hyungju Kwon in
Google Scholar
PubMed
Search for other papers by Young Jun Chai in
Google Scholar
PubMed
Search for other papers by Su-jin Kim in
Google Scholar
PubMed
Search for other papers by Kyu Eun Lee in
Google Scholar
PubMed
is no information for four patients. In high VDR group, 11 patients had locoregional and six patients had distant recurrence ( P value from Fisher’s exact test = 0.002). Figure 2 illustrates recurrence-free survival difference for two VDR
Search for other papers by Sandeep Kumar Parvathareddy in
Google Scholar
PubMed
Search for other papers by Abdul K Siraj in
Google Scholar
PubMed
Search for other papers by Zeeshan Qadri in
Google Scholar
PubMed
Search for other papers by Saeeda O Ahmed in
Google Scholar
PubMed
Search for other papers by Felisa DeVera in
Google Scholar
PubMed
Search for other papers by Saif Al-Sobhi in
Google Scholar
PubMed
Search for other papers by Fouad Al-Dayel in
Google Scholar
PubMed
Search for other papers by Khawla S Al-Kuraya in
Google Scholar
PubMed
defined as the number of metastatic LNs divided by the number of LNs resected. To determine the cut-off value for LNR, we used the receiver operating characteristic (ROC) curve analysis. Using recurrence-free survival as the outcome, we calculated the area
National Center for Neurological Disorders, Shanghai, China
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
Neurosurgical Institute of Fudan University, Shanghai, China
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China
Search for other papers by Nidan Qiao in
Google Scholar
PubMed
Search for other papers by Haixia Cheng in
Google Scholar
PubMed
Search for other papers by Zhaoyun Zhang in
Google Scholar
PubMed
Search for other papers by Hongying Ye in
Google Scholar
PubMed
National Center for Neurological Disorders, Shanghai, China
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
Neurosurgical Institute of Fudan University, Shanghai, China
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China
Search for other papers by Ming Shen in
Google Scholar
PubMed
National Center for Neurological Disorders, Shanghai, China
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
Neurosurgical Institute of Fudan University, Shanghai, China
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China
Search for other papers by Xuefei Shou in
Google Scholar
PubMed
National Center for Neurological Disorders, Shanghai, China
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
Neurosurgical Institute of Fudan University, Shanghai, China
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China
Search for other papers by Xiaoyun Cao in
Google Scholar
PubMed
National Center for Neurological Disorders, Shanghai, China
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
Neurosurgical Institute of Fudan University, Shanghai, China
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China
Department of Pathology, Huashan Hospital, Shanghai Medical School, Shanghai, China
Search for other papers by Hong Chen in
Google Scholar
PubMed
National Center for Neurological Disorders, Shanghai, China
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
Neurosurgical Institute of Fudan University, Shanghai, China
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China
Search for other papers by Xiang Zhou in
Google Scholar
PubMed
National Center for Neurological Disorders, Shanghai, China
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
Neurosurgical Institute of Fudan University, Shanghai, China
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China
Search for other papers by Yongfei Wang in
Google Scholar
PubMed
National Center for Neurological Disorders, Shanghai, China
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
Neurosurgical Institute of Fudan University, Shanghai, China
Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, China
Search for other papers by Yao Zhao in
Google Scholar
PubMed
insipidus. During the short follow-up (24 months (IQR: 12–48 months)), three patients (two in the SCO group and one in the PC group) relapsed after the initial surgery, suggesting the 2-year recurrence-free survival rate of 90.9% in patients with PCs and
Search for other papers by Lauren E Henke in
Google Scholar
PubMed
Search for other papers by John D Pfeifer in
Google Scholar
PubMed
Search for other papers by Thomas J Baranski in
Google Scholar
PubMed
Search for other papers by Todd DeWees in
Google Scholar
PubMed
Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri, USA
Search for other papers by Perry W Grigsby in
Google Scholar
PubMed
of data with continuous variables, while chi-squared tests were used for dichotomous data. All variables associated with the BRAF mutation, recurrence-free survival (RFS) or disease-specific survival (DSS) at the P < 0.05 level were entered into
Search for other papers by Jung Soo Lim in
Google Scholar
PubMed
Search for other papers by Seung-Eun Lee in
Google Scholar
PubMed
Search for other papers by Jung Hee Kim in
Google Scholar
PubMed
Search for other papers by Jae Hyeon Kim in
Google Scholar
PubMed
Search for other papers by The Korean Adrenal Gland and Endocrine Hypertension Study Group, Korean Endocrine Society in
Google Scholar
PubMed
Purpose
To evaluate the clinical characteristics and prognostic factors in patients with adrenocortical carcinoma (ACC) in South Korea.
Methods
A nationwide, registry-based survey was conducted to identify pathologically proven ACC at 25 tertiary care centers in South Korea between 2000 and 2014. Cox proportional hazard model and log-rank test were adopted for survival analysis.
Results
Two hundred four patients with ACC were identified, with a median follow-up duration of 20 months (IQR 5–52 months). The median age at diagnosis was 51.5 years (IQR 40–65.8 years), and ACC was prevalent in women (n = 110, 53.9%). Abdominal pain was the most common clinical symptom (n = 70, 40.2%), and ENSAT stage 2 was most common (n = 62, 30.4%) at the time of diagnosis. One hundred sixty-nine patients underwent operation, while 17 were treated with other modalities. The remission rate was 48%, and median recurrence-free survival time was 46 months. Estimated 5-year recurrence-free rate was 44.7%. There were more women, large tumor, atypical mitosis, venous invasion, and higher mitotic count in cancer recurrence group. Estimated 5-year overall survival and disease-specific survival rates were 64.5 and 70.6%, respectively. Higher ENSAT stage and advanced pathologic characteristics were risk factors for all-cause mortality of ACC. Large tumor size and cortisol-secreting tumor were additional risk factors for ACC-specific death.
Conclusions
We report the first epidemiologic study regarding ACC in an Asian population. ENSAT stage 4; lymph node involvement; non-operative group; and invasion of vein, sinusoid, or capsule were associated with an increased risk for all-cause mortality.
Search for other papers by Maria Luisa Garo in
Google Scholar
PubMed
Search for other papers by Désirée Deandreis in
Google Scholar
PubMed
Search for other papers by Alfredo Campennì in
Google Scholar
PubMed
Search for other papers by Alexis Vrachimis in
Google Scholar
PubMed
Search for other papers by Petra Petranovic Ovcaricek in
Google Scholar
PubMed
Clinic for Nuclear Medicine, University Hospital of Zürich, Zürich, Switzerland
Search for other papers by Luca Giovanella in
Google Scholar
PubMed
survival; EXT VAL, external validation; INT VAL, internal validation; LLNM, lateral lymph node metastasis; NR, not reported; OS, overall survival; RRFS, regional recurrence-free survival; VAL, validation. Studies description More than 50
Search for other papers by Prachi Bansal in
Google Scholar
PubMed
Search for other papers by Anurag Lila in
Google Scholar
PubMed
Search for other papers by Manjunath Goroshi in
Google Scholar
PubMed
Search for other papers by Swati Jadhav in
Google Scholar
PubMed
Search for other papers by Nilesh Lomte in
Google Scholar
PubMed
Search for other papers by Kunal Thakkar in
Google Scholar
PubMed
Search for other papers by Atul Goel in
Google Scholar
PubMed
Search for other papers by Abhidha Shah in
Google Scholar
PubMed
Search for other papers by Shilpa Sankhe in
Google Scholar
PubMed
Search for other papers by Naina Goel in
Google Scholar
PubMed
Search for other papers by Neelam Jaguste in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
Search for other papers by Nalini Shah in
Google Scholar
PubMed
recurrence rate was 41% (48/117), and mean time to recurrence was 37.2 ± 27.8 (8–96) months. The Kaplan–Meier analysis for recurrence-free survival is shown in Fig. 1 . Figure 1 Kaplan–Meier curve showing recurrence-free survival of Cushing’s disease
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Yujie Ren in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Xue Han in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Yujiang Li in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Key Laboratory of TCM Syndrome and Treatment of Yingbing (Thyroid Disease) of State Administration of Traditional Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Guofang Chen in
Google Scholar
PubMed
Search for other papers by Lin Jiang in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Key Laboratory of TCM Syndrome and Treatment of Yingbing (Thyroid Disease) of State Administration of Traditional Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Chao Liu in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Shuhang Xu in
Google Scholar
PubMed
, which was calculated as follows: IAR (%) = Va/preoperative tumor volume × 100%. The primary outcomes included local tumor progression, recurrence-free survival (RFS), and delayed surgery. Local tumor progression was defined as any of the following ( 23
Search for other papers by Cristina Lamas in
Google Scholar
PubMed
Search for other papers by Elena Navarro in
Google Scholar
PubMed
Search for other papers by Anna Casterás in
Google Scholar
PubMed
Search for other papers by Paloma Portillo in
Google Scholar
PubMed
Search for other papers by Victoria Alcázar in
Google Scholar
PubMed
Search for other papers by María Calatayud in
Google Scholar
PubMed
Search for other papers by Cristina Álvarez-Escolá in
Google Scholar
PubMed
Search for other papers by Julia Sastre in
Google Scholar
PubMed
Search for other papers by Evangelina Boix in
Google Scholar
PubMed
Search for other papers by Lluis Forga in
Google Scholar
PubMed
Search for other papers by Almudena Vicente in
Google Scholar
PubMed
Search for other papers by Josep Oriola in
Google Scholar
PubMed
Search for other papers by Jordi Mesa in
Google Scholar
PubMed
Search for other papers by Nuria Valdés in
Google Scholar
PubMed
PHPT. The lower rate of hypoparathyroidism after <SPTX did not reach statistical significance, probably due to the small number of patients in each category. We could not statistically prove the differences in recurrence-free survival after different